Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles.

Van Kaer L.

Nat Rev Immunol. 2005 Jan;5(1):31-42. Review.

PMID:
15630427
2.

Immunoregulation of autoimmunity by natural killer T cells.

Linsen L, Somers V, Stinissen P.

Hum Immunol. 2005 Dec;66(12):1193-202. Epub 2006 Mar 31. Review.

PMID:
16690406
3.

iNKT-cell responses to glycolipids.

Parekh VV, Wilson MT, Van Kaer L.

Crit Rev Immunol. 2005;25(3):183-213. Review.

PMID:
16048435
4.

Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia.

Liu R, La Cava A, Bai XF, Jee Y, Price M, Campagnolo DI, Christadoss P, Vollmer TL, Van Kaer L, Shi FD.

J Immunol. 2005 Dec 15;175(12):7898-904.

5.

Natural killer T cells and autoimmune disease.

Wu L, Van Kaer L.

Curr Mol Med. 2009 Feb;9(1):4-14. Review.

PMID:
19199937
6.

Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.

Wu L, Gabriel CL, Parekh VV, Van Kaer L.

Tissue Antigens. 2009 Jun;73(6):535-45. doi: 10.1111/j.1399-0039.2009.01256.x. Epub 2009 Apr 8. Review.

PMID:
19392798
8.

Natural killer T cells as targets for immunotherapy of autoimmune diseases.

Van Kaer L.

Immunol Cell Biol. 2004 Jun;82(3):315-22. Review.

PMID:
15186263
9.

Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity.

Wilson SB, Delovitch TL.

Nat Rev Immunol. 2003 Mar;3(3):211-22. Review.

PMID:
12658269
10.

The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.

Pyz E, Naidenko O, Miyake S, Yamamura T, Berberich I, Cardell S, Kronenberg M, Herrmann T.

J Immunol. 2006 Jun 15;176(12):7447-55.

11.

Activation or anergy: NKT cells are stunned by alpha-galactosylceramide.

Sullivan BA, Kronenberg M.

J Clin Invest. 2005 Sep;115(9):2328-9.

12.

Role of invariant natural killer T cells in immune regulation and as potential therapeutic targets in autoimmune disease.

Van Kaer L.

Expert Rev Clin Immunol. 2006 Sep;2(5):745-57. doi: 10.1586/1744666X.2.5.745.

PMID:
20477630
13.

Ligand-dependent induction of noninflammatory dendritic cells by anergic invariant NKT cells minimizes autoimmune inflammation.

Wang J, Cho S, Ueno A, Cheng L, Xu BY, Desrosiers MD, Shi Y, Yang Y.

J Immunol. 2008 Aug 15;181(4):2438-45. Erratum in: J Immunol. 2008 Oct 15;181(8):5803. Xu, Bo-You [corrected to Xu, Bao-You].

14.

Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway.

Miellot A, Zhu R, Diem S, Boissier MC, Herbelin A, Bessis N.

Eur J Immunol. 2005 Dec;35(12):3704-13.

15.

Understanding the behavior of invariant NKT cells in autoimmune diseases.

Yamamura T, Sakuishi K, Ill├ęs Z, Miyake S.

J Neuroimmunol. 2007 Nov;191(1-2):8-15. Epub 2007 Oct 1. Review.

PMID:
17905445
16.

Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis.

Stanley AC, Zhou Y, Amante FH, Randall LM, Haque A, Pellicci DG, Hill GR, Smyth MJ, Godfrey DI, Engwerda CR.

PLoS Pathog. 2008 Feb 29;4(2):e1000028. doi: 10.1371/journal.ppat.1000028.

17.

[iNKT cells, a friend or a foe for autoimmune disease and allergy?].

Miyake S.

Nihon Rinsho Meneki Gakkai Kaishi. 2006 Feb;29(1):27-36. Review. Japanese.

18.

Polarization of natural killer T cells towards an NKT2 subpopulation occurs after stimulation with alpha-galactosylceramide and rhG-CSF in aplastic anemia.

Wang Y, Hu X, Guo C, Zhang Q, Peng J, Zhang J, Li L, Zhang T, Xu C.

Acta Haematol. 2008;119(3):178-86. doi: 10.1159/000137501. Epub 2008 Jun 6.

PMID:
18535366
19.

Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black x New Zealand White)F1 mice.

Forestier C, Molano A, Im JS, Dutronc Y, Diamond B, Davidson A, Illarionov PA, Besra GS, Porcelli SA.

J Immunol. 2005 Jul 15;175(2):763-70.

20.

Therapeutic manipulation of iNKT cells in autoimmunity: modes of action and potential risks.

Mars LT, Novak J, Liblau RS, Lehuen A.

Trends Immunol. 2004 Sep;25(9):471-6. Review.

PMID:
15324739

Supplemental Content

Support Center